Men and women experience pain relief differently; new study may help explain why women have more chronic pain and are less responsive to opioid treatments University of California – San Diego In a new study evaluating meditation for chronic lower back pain, researchers at University of California San Diego School of Medicine have discovered that...
Post
Mpox vaccine is safe and generates a robust antibody response in adolescents
NIH clinical trial addresses knowledge gap on vaccine use in adolescent populations Reports and Proceedings NIH/National Institute of Allergy and Infectious Diseases image: Colorized transmission electron micrograph of mpox virus particles (light green) found within VERO E6 cells (teal). The virus particles are in various stages of maturity, which accounts for differences in shape. Captured...
Post
Bacterial vaccine shows promise as cancer immunotherapy
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells. Columbia University Irving Medical Center image: Engineered bacterial cells (purple) activate several parts of the immune system to attack tumor cells (gray). Credit: Columbia University Columbia researchers have engineered probiotic bacteria that educate...
Post
Breakthrough technology leads to life-saving treatment for deadly skin reaction
Spatial proteomics provides therapeutic approach for patients with toxic epidermal necrolysis – off-label use of JAK inhibitors in first patients worldwide leads to complete recovery Max-Planck-Gesellschaft image: Epidermal detachment by toxic Epidermal Necrolysis. Credit: T. Nordmann The researchers used spatial proteomics to analyze skin samples from patients with toxic epidermal necrolysis. This cutting-edge approach, known...
Post
Protein interactions: Who is partying with whom and who is ruining the party?
image: A hustle and bustle like at the Zurich Street Parade: inside a cell, countless different proteins interact with each other around the cell nucleus. Credit: Cathy Marulli / ETH Zurich Inside cells, it’s like in a packed dance club: hundreds are partying. Some keep to themselves, others make their way through the crowd, chatting...
Post
New study reveals promising therapy that blocks microRNAs to treat myotonic dystrophy type 1
Integrated evaluation of the antimiR’s therapeutic potential. Credit: Science Advances (2024). DOI: 10.1126/sciadv.adn6525 A team of researchers has identified a promising therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1), a complex genetic disorder caused by an abnormally high number of CTG repeats (a specific type of RNA sequence) in the DMPK gene. The results...
Post
People displaced by hurricanes face anxiety and a long road to recovery, surveys show
Credit: CC0 Public Domain The trauma of natural disasters doesn’t end when the storm or wildfire is gone, or even when communities are being put back together and homes have been rebuilt. For many people, being displaced by a disaster has long-term consequences that often aren’t obvious or considered in disaster aid decisions. We study public...
Post
Researchers evaluate beneficial effects of fermented black garlic extract on prostate cancer
Effects of aged black garlic water extract (ABGE) on cell proliferation of control prostate (PNT-2) (a), androgen-dependent (LNCaP) (b), and androgen-independent (PC-3) (c) prostate cancer (PCa) cells. Cell proliferation and growth were evaluated by resazurin reagent after incubation for 24, 48, and 72 h of PNT-2, LNCaP, and PC-3 cell lines with ABGE at different...
Post
FDA says compounding pharmacies can keep making weight-loss med tirzepatide, for now
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list. What prompted the FDA to reconsider its decision? On Oct. 7, a compounding trade group filed a lawsuit challenging the agency’s action, saying there was...
Post
FDA approves Hympavzi for hemophilia
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors. Unlike other drugs that replace a clotting factor, Hympavzi is...